Elisabeth Bendstrup

Nintedanib in idiopathic pulmonary fibrosis: Practical management recommendations for potential adverse events

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review


  • Elisabeth Bendstrup
  • Wim Wuyts, Dentistry, University Hospitals, KU Leuven, Instituut voor Kern- en Stralingsfysica
  • ,
  • Tiago Alfaro, Coimbra University Hospital
  • ,
  • Nazia Chaudhuri, Manchester University
  • ,
  • Robin Cornelissen, Erasmus Medical Center Cancer Institute
  • ,
  • Michael Kreuter, University of Heidelberg
  • ,
  • Kirsten Melgaard Nielsen
  • Anna Marie B. Münster, Unit of Thrombosis Research, University of Southern Denmark, Esbjerg
  • ,
  • Marjukka Myllärniemi, Helsinki University Central Hospital
  • ,
  • Claudia Ravaglia, Ospedale Gb Morgagni
  • ,
  • Tim Vanuytsel, Instituut voor Kern- en Stralingsfysica
  • ,
  • Marlies Wijsenbeek, Erasmus University Medical Center

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a dismal survival rate of only 3 years and no curative pharmacological therapy. The recent approval of 2 anti-fibrotic drugs (nintedanib and pirfenidone) that slow disease progression has provided some hope for patients. However, effectively managing anti-fibrotic treatment can be a challenge due to tolerability issues, the presence of pulmonary and extra-pulmonary comorbidities, and the need for concomitant medications in many patients. In general, making clear evidence-based decisions can be difficult for physicians because patients with comorbidities are often excluded from clinical trials. Since currently anti-fibrotic drugs are the only effective therapeutics capable of slowing disease progression, it is imperative that all treatment options are thoroughly evaluated and exhausted in each individual, irrespective of complicating factors, to permit the best outcome for the patient. In this review, we present data from clinical trials, post hoc analyses, post-marketing surveillance, and real-world studies that are relevant to the management of nintedanib treatment. In addition, we also provide practical recommendations developed by a multidisciplinary panel of experts for the management of nintedanib treatment in patients with IPF associated complications and those experiencing gastrointestinal side effects.

Original languageEnglish
Pages (from-to)173-184
Number of pages12
Publication statusPublished - Feb 2019

    Research areas

  • Expert opinion, Idiopathic pulmonary fibrosis, Nintedanib, Treatment

See relations at Aarhus University Citationformats

ID: 150097818